Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + Chemotherapy in Advanced Pancreatic Cancer
NCT05859750Phase 2Recruiting
- Sponsor
- Akeso, Inc.
- Start
- May 2023
- Primary completion
- Jun 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of cadonilimab in pancreatic ductal adenocarcinoma (PDAC) (4 arms), sponsored by Akeso, Inc. Primary endpoints: Objective Response Rate at 2 years and Number of subjects experiencing adverse events. Started May 2023; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05859750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05859750.